All In Biotech

Drug Trial Radar · NCT05823012

Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism

A Phase 2, Multicenter, Non-Randomized, Open-Label, Single Arm, Self-controlled Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism

Last checked: Nov 20, 2026Latest source record: Jul 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

46

Actual

Start

May 15, 2023

Primary completion

Feb 22, 2024

Study completion Feb 22, 2024

Sponsor

Lead sponsor
Xeris PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Apr 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a non-randomized, open-label, single arm, self-controlled study of XP-8121 (levothyroxine sodium) to determine a target dose conversion factor from stably dosed oral levothyroxine to XP-8121 (levothyroxine sodium) in patients with hypothyroidism and to assess the safety and tolerability of XP-8121(levothyroxine sodium) after once weekly subcutaneous injections. This study includes the following periods: Screening, Titration Period, and Maintenance Period. The study will conclude with an End of Maintenance Visit or Early Termination (ET) Visit.

Conditions

  • Hypothyroidism

Interventions

  • levothyroxine sodiumDrug

    Levothyroxine sodium 10 mg/mL

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Conversion FactorTime frame: Day 29 of the Maintenance Period
  2. Tolerability Assessment: Modified Draize Scale - ErythemaTime frame: Week 1 Dosing in Titration Period through Day 22 Dosing in Maintenance Period
  3. Tolerability Assessment: Modified Draize Scale - EdemaTime frame: Week 1 Dosing in Titration Period through Day 22 Dosing in Maintenance Period
  4. Tolerability Assessments: Injection Site Discomfort EvaluationTime frame: Week 1 dosing in the Titration Period through Day 22 dosing in the Maintenance Period

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • ProSciento, Inc.

    Chula Vista, California

  • Catalina Research Institute, L.L.C.

    Montclair, California

  • Panax Clinical Research, LLC

    Miami Lakes, Florida

  • American Research Corporation

    San Antonio, Texas

  • Mt. Olympus Medical Research, LLC

    Sugar Land, Texas

  • Rainier Clinical Research Center

    Renton, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.